Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRD Positive Advanced Ovarian Cancer”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Large-scale testing (Phase 3)Looking for participantsNCT06954584
What this trial is testing

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Tongji Hospital 424
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Testing effectiveness (Phase 2)Study completedNCT04417192
What this trial is testing

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

Who this might be right for
Ovarian Cancer
National Cancer Center Hospital East 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07033819
What this trial is testing

Neoadjuvant Treatment of Ovarian Cancer With Fluazoparib in Combination With Apatinib

Who this might be right for
Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 48
Testing effectiveness (Phase 2)Looking for participantsNCT06141265
What this trial is testing

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

Who this might be right for
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Peking University Cancer Hospital & Institute 116
Testing effectiveness (Phase 2)Ended earlyNCT06065059
What this trial is testing

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Who this might be right for
Breast CancerOvarian CancerPancreas Cancer+5 more
Tango Therapeutics, Inc. 7